Virginia Bio’s New Website is Live
RICHMOND, VA. – Virginia Bio, the premier statewide non-profit association of the life science industry in Virginia, is pleased to announce the launch of its new and refreshed website. This redesigned site offers quick and easy access to essential information and features while offering a more comprehensive understanding of the Virginia life science ecosystem and overall member benefits. It has a responsive layout for all platforms so busy members can access the information they need from any device. The website better reflects our association and member community, while offering...
Read MoreGrid Therapeutics Closes Series B Financing
DURHAM, N.C. – Grid Therapeutics, LLC, a biotechnology company developing a first-in-class, novel human-derived targeted immunotherapy for cancer, today announced the closing of its Series B financing. Grid will use the proceeds from the financing to accelerate and expand the development of Grid’s lead therapeutic candidate, GT103, for the treatment of solid tumors, and to prepare for clinical trials in cancer patients scheduled to commence in early 2019. Grid’s foundation is the innovative science developed by Edward F. Patz, Jr., MD, and his team of scientists at Duke University...
Read MoreRegistration Open for SEBIO 2018!!
Celebrating its 20th Anniversary, the Southeast BIO Investor & Partnering Forum returns to Atlanta on November 13-14, 2018 with a new format, new networking opportunities, and new investment prospects. Bookmark the conference webpage to stay up-to-date on the Forum including announcements on the program, details on exclusive networking, and to ensure your spot by registering...
Read MoreVero Biotech Moves HQ to Atlanta
ATLANTA, GA. – Atlanta has reeled in another headquarters tenant. Vero Biotech recently wrapped up the relocation of its home base from Cocoa, Fla., to Georgia Tech’s Technology Enterprise Park (TEP) in Midtown Atlanta. Vero Biotech has set up shop in a nearly 15,600-square-foot space at 387 Technology Circle NW. With its name on the tenant roster of the 236,700-square-foot office and lab building, the emerging biotechnology company has attained a certain instant cachet, as the 11-acre park is widely considered the premier biotech research park in the city. “The decision to move...
Read MoreGlaucoma treatment device startup Camras Vision lands $5.7M
RESEARCH TRIANGLE PARK, N.C. – Startup Camras Vision, which is developing a device to address glaucoma, has closed on $5.7 million in venture capital funding. Camras plans to use the funding to support four clinical trials, including a pilot study in the U.S. A variety of investors participated, including the Triangle Venture Alliance, which is a partnership among Duke University, the University of North Carolina and NC State University angel groups. “Researchers and scientists from universities across the Triangle region often join forces to collaborate on innovations,” said...
Read MoreEuro biotech firm UCB acquires Duke genomics startup Element for up to $30M
DURHAM, N.C. – Element Genomics, a three-year-old Duke University spin-off focusing on genomic research, has been acquired by Belgium-based UCB for as much as $30 million. A priority for Element is a gene-editing technology known as CRISPR. UCB, a global biopharmaceutical firm which has a presence in the Triangle, said upfront payments and milestones based on success could push the deal value to a maximum of $30 million. “Element Genomics researchers have a stellar reputation and their scientific expertise in genomics and epigenomics will complement UCB’s, allowing us to deepen our...
Read More
Follow Us!